Austrália - inglês - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - bosentan monohydrate, quantity: 64.5 mg (equivalent: bosentan, qty 62.5 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

Tanzânia - inglês - Tanzania Medicinces & Medical Devices Authority

cipla limited, india - mask -

África do Sul - inglês - South African Health Products Regulatory Authority (SAHPRA)

cipla medpro manufacturing (pty) ltd - pellet - see ingredients - each capsule contains lopinavir 40,0 mg ritonavir 10,0 mg

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - erlotinib hydrochloride, quantity: 109.267 mg (equivalent: erlotinib, qty 100 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; sodium starch glycollate type a; magnesium stearate; sodium lauryl sulfate; titanium dioxide; hypromellose; hyprolose; macrogol 400 - non-small cell lung cancer erlotinib cipla is indicated for the first-line treatment of patients with advanced (stage iiib) or metasttic (stega iv) non-small cell lung cancer (nsclc) with activating egfr mutations. erlotinib cipla is indicated for matintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfr mutations who have not progressed on first-line chemotherapy. erlotinib cipla is also indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer after failure of prior chemotherapy.,pancreatic cancer erlotinib cipla in combination with gemcitabine is indicated for the treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - erlotinib hydrochloride, quantity: 163.9 mg (equivalent: erlotinib, qty 150 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; sodium starch glycollate type a; magnesium stearate; sodium lauryl sulfate; titanium dioxide; hypromellose; hyprolose; macrogol 400 - non-small cell lung cancer erlotinib cipla is indicated for the first-line treatment of patients with advanced (stage iiib) or metasttic (stega iv) non-small cell lung cancer (nsclc) with activating egfr mutations. erlotinib cipla is indicated for matintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfr mutations who have not progressed on first-line chemotherapy. erlotinib cipla is also indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer after failure of prior chemotherapy.,pancreatic cancer erlotinib cipla in combination with gemcitabine is indicated for the treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - erlotinib hydrochloride, quantity: 27.317 mg (equivalent: erlotinib, qty 25 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; sodium starch glycollate type a; magnesium stearate; sodium lauryl sulfate; titanium dioxide; hypromellose; hyprolose; macrogol 400 - non-small cell lung cancer erlotinib cipla is indicated for the first-line treatment of patients with advanced (stage iiib) or metasttic (stega iv) non-small cell lung cancer (nsclc) with activating egfr mutations. erlotinib cipla is indicated for matintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfr mutations who have not progressed on first-line chemotherapy. erlotinib cipla is also indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer after failure of prior chemotherapy.,pancreatic cancer erlotinib cipla in combination with gemcitabine is indicated for the treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

África do Sul - inglês - South African Health Products Regulatory Authority (SAHPRA)

cipla medpro (pty) ltd - injection - not indicated - none

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - cinacalcet hydrochloride, quantity: 99.191 mg (equivalent: cinacalcet, qty 90 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; pregelatinised starch; crospovidone; povidone; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cipla cinacalcet may be used to treat the biochemical manifestations of secondary hyperparathyroidism (hpt) in patients with end stage renal disease, receiving dialysis (see section 5.1 pharmacodynamic properties, clinical trials). cipla cinacalcet should be used as adjunctive therapy.,cipla cinacalcet is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma.,cipla cinacalcet may be used to treat the biochemical manifestations of primary hpt in patients for whom parathyroidectomy is not a treatment option.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - cinacalcet hydrochloride, quantity: 66.128 mg (equivalent: cinacalcet, qty 60 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; pregelatinised starch; crospovidone; povidone; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cipla cinacalcet may be used to treat the biochemical manifestations of secondary hyperparathyroidism (hpt) in patients with end stage renal disease, receiving dialysis (see section 5.1 pharmacodynamic properties, clinical trials). cipla cinacalcet should be used as adjunctive therapy.,cipla cinacalcet is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma.,cipla cinacalcet may be used to treat the biochemical manifestations of primary hpt in patients for whom parathyroidectomy is not a treatment option.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - cinacalcet hydrochloride, quantity: 33.064 mg (equivalent: cinacalcet, qty 30 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; pregelatinised starch; crospovidone; povidone; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cipla cinacalcet may be used to treat the biochemical manifestations of secondary hyperparathyroidism (hpt) in patients with end stage renal disease, receiving dialysis (see section 5.1 pharmacodynamic properties, clinical trials). cipla cinacalcet should be used as adjunctive therapy.,cipla cinacalcet is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma.,cipla cinacalcet may be used to treat the biochemical manifestations of primary hpt in patients for whom parathyroidectomy is not a treatment option.